(Q35927194)

11 August 2017

1 reference

title

The toxicology of HMG-CoA reductase inhibitors: prediction of human risk (English)

1 reference

11 August 2017

James S MacDonald

1

1 reference

PubMed ID

15503662

11 August 2017

Margaretann M Halleck

series ordinal

2

1 reference

PubMed ID

15503662

11 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

11 August 2017

Toxicologic Pathology

1 reference

11 August 2017

32 Suppl 2

1 reference

11 August 2017

26-41

1 reference

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

11 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Association of HMG-CoA reductase inhibitors with neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Cholesterol and cataracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Geranylgeranyl pyrophosphate counteracts the cataractogenic effect of lovastatin on cultured rat lenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Learning from the cerivastatin experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Statins and risk of polyneuropathy: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Myopathy and rhabdomyolysis with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

A general cardiovascular risk profile: The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

The role of maternal toxicity in lovastatin-induced developmental toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Preclinical evaluation of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Lipid-lowering drugs: are adverse effects predictable and reversible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Carcinogenicity of lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Plasma mevalonate as a measure of cholesterol synthesis in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Defining patient risks from expanded preventive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

How well tolerated are lipid-lowering drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01926230490462057

10.1080/01926230490462057

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15503662